Mycophenolsyre Tillomed (Mycophenolic Acid)

Mycophenolic Acid, the active ingredient in Mycophenolsyre Tillomed, is an antimetabolite immunosuppressant presented as an oral formulation for oral use. It is employed to reduce the risk of organ transplant rejection and to manage certain autoimmune disorders such as lupus nephritis and vasculitis, acting primarily on lymphocyte proliferation.

GNH USA supplies Mycophenolsyre Tillomed as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, specialty clinics and pharmacies worldwide, with established global reliable robust quality‑assured manufacturing and distribution networks.

Mycophenolic Acid is used to modulate immune activity in conditions where suppression of lymphocyte proliferation is required.

- Organ transplant rejection: helps prevent acute and chronic rejection by inhibiting immune response to the graft. - Lupus nephritis: reduces renal inflammation and proteinuria in patients with systemic lupus erythematosus affecting the kidneys. - ANCA‑associated vasculitis: assists in controlling systemic vasculitis by limiting auto‑immune mediated vessel damage.

Mycophenolic Acid may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Gastrointestinal upset: nausea, vomiting, diarrhea, or abdominal discomfort. - Infections: heightened risk of bacterial, viral or fungal infections. - Hematologic changes: leukopenia, anemia or thrombocytopenia.

Serious or Rare Side Effects: - Severe opportunistic infection: e.g., Pneumocystis jirovecii pneumonia. - Progressive multifocal leukoencephalopathy (PML): rare demyelinating brain disease. - Bone marrow failure: aplastic anemia or pancytopenia.

When prescribing Mycophenolic Acid, clinicians should consider several precautionary measures to minimise risk. - Monitor blood counts: regular CBC to detect leukopenia or anemia. - Assess renal function: adjust therapy if creatinine clearance declines. - Evaluate liver enzymes: periodic LFTs for hepatotoxicity. - Avoid live vaccines: increased infection risk makes live attenuated vaccines contraindicated. - Pregnancy and lactation: discuss potential risks and consider alternative therapy. - Store at ambient temperature: keep below 25 °C in the original container, protect from moisture and light.

Mycophenolic Acid can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Antacids containing aluminum or magnesium: reduce absorption of Mycophenolic Acid. - Azathioprine: additive bone marrow suppression. - Cyclosporine or tacrolimus: increased mycophenolic acid exposure leading to toxicity.

Moderate Interactions (Monitor Closely): - Rifampin: induces metabolism, decreasing drug levels. - Valganciclovir: may increase risk of hematologic toxicity. - Cholestyramine: may bind and lower drug absorption.